Feature | April 25, 2007 | Cristen C. Bolan

Nuclear Medicine, IT Tie the Knot via InfoSNM

Frederic H. Fahey, D.Sc., Division of Nuclear Medicine, Children's Hospital Boston, is the Scientific Program Committee Chair for the Society of Nuclear Medicine.

The theme of SNM’s 54th Annual Meeting to be held on June 2–6 in Washington, D.C., this year is “SNM: Advances in Personalized Medicine.” As part of the conference’s goal of presenting recent improvements in the diagnosis and treatment of life-threatening cancer, heart disease and brain disorders, it has initiated a new program, InfoSNM, to leverage IT for more effective use of data in the research, educational and clinical setting. The InfoSNM program is designed to allow attendees to participate in interactive computer presentations and educational offerings on the novel applications of computers and information science in molecular imaging and nuclear medicine.
Imaging Technology News (ITN) spoke with the SNM Scientific Program Committee Chair Frederic H. Fahey, D.Sc. of Children's Hospital Boston Division of Nuclear Medicine about what InfoSNM will offer clinicians.

ITN: There is a new feature this year at SNM called the InfoSNM program. What is the objective of this program?

Frederic H. Fahey (FF): In the last few years, computers have become more important in all aspects of nuclear medicine and molecular imaging, including education and research, and there has in the past not really been an appropriated forum within the SNM meeting to present that kind of information or help those who are trying to come up to speed on the new advances in IT in nuclear medicine and molecular imaging. So I tried to provide such a forum.
This new program is broken into two parts. One will have an educational component – a computer classroom that will run some workshops that deal with general things that aren’t specific molecular imaging. For example, since we’re in Washington, D.C., the National Library of Medicine will give a workshop on how to do better Pub Med searches. And there will be tutorials on the use of other processing and image analysis tools, for example, the uses of NIH image J as it applies to processing nuclear medicine images – that is a freeware image processing package.
The other part of the program is that we have entertained a new abstract category this year. Usually abstracts that are submitted are trying to elicit new science. This was not necessarily new science but novel approaches of using computers in the context of science or education or in the clinic. We are looking at new applications to be used within the context of nuclear medicine and molecular imaging, and we accepted 23 abstracts.

ITN: Will the combining of nuclear medicine and molecular imaging with IT address developments in personalized medicine?

FF: It touches on personalized medicine, yet it’s broader than that. In clinic, computers allow you to have access much more data about a particular patient when you are going to do a study on them. And as we move from the lab and molecular imaging into the clinic we will have access to that kind of information. Also, just more efficient use of computers as a research tool and educational tool.

ITN: SNM will feature seminars that cover emerging clinical applications of SPECT/CT and hot topics in PET/CT. Specifically, what are these applications and topics?

FF: PET/CT over the last few years has become very popular because it has addressed a particular need in oncologic PET, being able to correlate both disease and normal uptake in these patients and allow a more accurate reading of the data. Because of that, there is more access to PET/CT and we are going to see at this meeting the application of PET/CT in other arenas besides oncology, using PET/CT in research on imaging arthrosclerosis or inflammation or infection.
We will see SPECT/CT applications beyond cardiology. The role of SPECT/CT is at an earlier phase of evolution, and we will see some applications in cardiology, but as well in oncology and general nuclear medicine where SPECT/CT also has a role.

Related Content

ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Imaging | August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
July 7, 2017 — Blood clots in veins a
Sponsored Content | Videos | Clinical Decision Support | June 29, 2017
Rami Doukky, M.D., system chair, Division of Cardiology, professor of medicine, Cook County Health and Hospitals Syst
Dual-Agent PET/MR With Time of Flight Detects More Cancer

Tc-99m MDP bone scan (left) is negative for osseous lesions. NaF/FDG PET/MRI (right and second slide) confirms absence of bone metastases, but shows liver metastases. Image courtesy of Stanford University.

News | PET-MRI | June 20, 2017
Simultaneous injections of the radiopharmaceuticals fluorine-18 fluorodeoxyglucose (18F-FDG) and 18F-sodium fluoride (...
Combined Optical and Molecular Imaging Could Guide Breast-Conserving Surgery

WLE specimen from a patient with a grade 3, ER-/HER2-, no special type (NST) carcinoma. (A) Cerenkov image; (B) Grey-scale photographic image overlaid with Cerenkov signal. An increased signal from the tumor is visible (white arrows); mean radiance is 871 ± 131 photons/s/cm2/sr, mean TBR is 3.22. Both surgeons measured the posterior margin (outlined in blue) as 2 mm (small arrow); a cavity shaving would have been performed if the image had been available intraoperatively. The medial margin (outlined in green) measured >5 mm by both surgeons. Pathology ink prevented assessing the lateral margin; a phosphorescent signal is visible (open arrows). (C) Specimen radiography image. The absence of one surgical clip to mark the anterior margin, and the odd position of the superior margin clip (white arrow) prevented reliable margin assessment. (D) Combined histopathology image from two adjacent pathology slides on which the posterior margin (bottom of image) and part of the primary tumor are visible (open arrows). The distance from the posterior margin measured 3 mm microscopically (double arrow). The medial margin is > 5 mm (not present in image). Credit: A. D. Purushotham, M.D., King’s College London, UK

News | Nuclear Imaging | June 20, 2017
June 20, 2017 — Breast-conserving surgery (BCS) is the primary treatment for early-stage...
Overlay Init